文献速递临床生化分子诊断临床免疫

肾上腺皮质癌的多组学生物标志物:临床化学视角

Multi-omics biomarker in adrenocortical carcinoma: a clinical-chemistry perspective.
PubMed 文献 · Clin Chim Acta · 2026-05-20

本文为叙述性综述,评估了246篇关于肾上腺皮质癌(ACC)四个多组学层面的原始研究。基因组与转录组分析揭示了优于ENSAT分期的预后分子亚型;组织与循环蛋白组学识别出HNRNPA1、KPNA2、SOAT1及血浆AgRP等靶点;尿与血清类固醇代谢组学在2017例前瞻性EURINE-ACT队列中验证了超过85%的诊断准确性。文章还讨论了各标志物层转化为临床化学实验室应用前需满足的分析前、分析及室间标准化要求。

要点

  • 基因组与转录组分子亚型预后优于ENSAT分期。
  • 类固醇代谢组学在大型队列中诊断准确性超过85%。
  • 多组学分类识别出两个具有治疗意义的生物学亚型。

核心结论

  • 多组学标志物可弥补传统临床化学与组织学评分在非功能肿瘤检测、预后预测及术后微小残留病监测方面的不足。

研究设计与样本

  • 叙述性综述,评估了246篇关于ACC四个多组学层面的原始研究文献。

主要发现

  • 基因组与转录组分析(包括TCGA-ACC泛基因组图谱)揭示了反复出现的驱动突变及预后分子亚型,后者优于ENSAT分期。
  • 组织与循环蛋白组学识别出HNRNPA1、KPNA2、SOAT1及血浆AgRP作为诊断和药物蛋白组学靶点。
  • 尿与血清类固醇代谢组学(GC-MS与液相色谱-串联质谱)在2017例前瞻性EURINE-ACT队列中验证,提供超过85%的临床可操作诊断准确性,并对术后复发监测有信息价值。
  • 多组学分类一致识别出两个具有治疗意义的独特生物学亚型。

关键数值与推荐

  • ACC发病率0.7-2.0/百万人/年,ENSAT IV期5年生存率低于15%。
  • 类固醇代谢组学在2017例前瞻性EURINE-ACT队列中诊断准确性超过85%。

临床怎么用

  • 临床化学实验室常规检测血清皮质醇、DHEAS及24小时尿游离皮质醇用于功能肿瘤检测,但无法检出非功能肿瘤。
  • 多组学策略可用于ACC诊断、预后及复发检测,但各标志物层需满足分析前、分析及室间标准化要求后方可转化至临床化学实验室。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Adrenocortical carcinoma (ACC) is a rare but aggressive endocrine tumor (incidence 0.7-2.0 per million per year) with a 5-year survival rate of less than 15% at the European Network for the Study of Adrenal Tumors stage IV. The standard diagnostic workup in clinical chemistry laboratories for the detection of functional tumors (serum cortisol, DHEAS, and 24 h urinary free cortisol) and the Weiss/Helsinki histological scoring system cannot detect non-functioning tumors, lacks a standardized approach for predicting prognosis, and does not have a validated minimal-residual-disease marker for postoperative monitoring. This narrative review evaluated 246 original research publications on four multi-omic layers in relation to clinical laboratories. Genomic and transcriptomic analyses, including TCGA-ACC pan-genomic profiling, revealed recurrent driver mutations and prognostic molecular subtypes that outperform the ENSAT staging. Tissue and circulating proteomic analyses identified HNRNPA1, KPNA2, SOAT1, and plasma AgRP as diagnostic and pharmacoproteomic targets. Urinary and serum steroid metabolomics (GC-MS and liquid chromatography-tandem mass spectrometry) validated in a 2017-patient prospective EURINE-ACT cohort provided clinically actionable diagnostic accuracy of over 85% and proved informative for post-surgical recurrence monitoring. Multi-omics classification consistently identifies two distinct biologically based subtypes with therapeutic implications. We also discuss the pre-analytical, analytical, and inter-laboratory standardization requirements that must be met before each biomarker layer can be translated to the clinical chemistry laboratory and advocate a multi-omic implementation strategy for ACC diagnosis, prognosis, and recurrence detection.

来源:Clin Chim Acta,查看原文。版权归原作者所有。

引用

  1. Gupta G, Patil DJ, Patel JR, et al. Multi-omics biomarker in adrenocortical carcinoma: a clinical-chemistry perspective. Clin Chim Acta. 2026. PMID: 42167637. doi:10.1016/j.cca.2026.121103

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。